The DILI-sim Initiative engages a world-class Scientific Advisory Board (SAB) for DILIsym development guidance. The DILI-sim Initiative SAB currently consists of 7 world-renowned scientists representing many scientific disciplines relevant to drug-induced liver injury. In addition, members of the SAB have extensive experience in the areas of medicine, pharmacology, and immunology with publications spanning numerous disciplines and journals. The SAB members provide strategic guidance and direction for our research and scientific programs, engaging individually with the DILIsym development team to address specific scientific areas, participate in DILIsym Review Sessions, and gather for an annual progress update. Board members are appointed in their personal capacity and not as representatives of their respective universities or of any other entities with which they may be affiliated.